Late-stage asthma clinical trials have relied on traditional inflammation assessment tools, such as fractional exhaled nitric oxide (Feno), total IgE levels, and peripheral blood eosinophils, to stratify T2-high from T2-low endotypes. Here, IGHE is linked to asthma.